Tracker › Companies › InMed Pharmaceuticals Inc.
3 No sign of it. We found no public evidence tying InMed Pharmaceuticals Inc.'s cuts to AI.
Every tracked 2026 layoff at InMed Pharmaceuticals Inc., newest first. Scores are 0–100: how strongly the public evidence ties the cuts to AI. Sources are linked on each one.
AI score 3/100 (Minimal) · 80% interval 2–3 · evidence grade D · US · Pharma / Chemicals
Stated reason: As previously reported, H.R. 5371, the “Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026” (the “Act”) in its current form and without further amendment, will have a material negative impact on BayMedica LLC (“BayMedica”), a wholly owned subsidiary of InMed Pharmaceuticals Inc. (the “Company”). Specifically, certain aspects of BayMedica’s …
Why 3: Plant, store or site closure · Drivers: contrary evidence −0.7, industry AI exposure +0.5
Evidence: SEC filing. Signals: attribution 0.0, primary source 0.0, exec statement 0.0, role exposure 0.653, industry exposure 0.712, AI investment 0.0, contrary evidence 0.4 · typical Health Care & Pharma roles (no roles named)
Headcount basis: not disclosed
Scores are evidence-based estimates from a published model, not findings that AI caused any layoff. Spot something wrong or missing? Tell us.
Other Health Care & Pharma layoffs we track.
Health Care & Pharma · 3,800 workers
Health Care & Pharma · 648 workers
Health Care & Pharma · 419 workers
Health Care & Pharma · 365 workers
Health Care & Pharma · 300 workers
Health Care & Pharma · 120 workers
